Replies to post #218493 on Biotech Values

[DewDiligence]

NGM282 is not part of the MRK-NGM collaboration:

https://www.merck.com/licensing/our-partnership/ngm-and-merck.html

NGM’s lead program, NGM282, currently in clinical development for primary biliary cirrhosis (PBC) and NASH, as well as programs that are the focus of NGM’s pre-existing collaboration agreements, are not subject to the option under the Merck collaboration.

The contemporaneous iHub post for this collaboration (which no one commented on) is in #msg-111075304.